Robert W. Baird Issues Positive Forecast for Cooper Companies (NASDAQ:COO) Stock Price

Cooper Companies (NASDAQ:COO) had its price target hoisted by Robert W. Baird from $85.00 to $98.00 in a report published on Friday, Marketbeat reports. They currently have an outperform rating on the medical device company’s stock.

Several other equities research analysts have also weighed in on the company. The Goldman Sachs Group set a $64.00 target price on Cooper Companies and gave the stock a “sell” rating in a research report on Wednesday, October 1st. Wells Fargo & Company reiterated an “equal weight” rating and issued a $72.00 price target on shares of Cooper Companies in a research note on Thursday, November 13th. Piper Sandler restated an “overweight” rating and set a $94.00 price objective (up previously from $83.00) on shares of Cooper Companies in a research report on Friday. JPMorgan Chase & Co. lowered their target price on shares of Cooper Companies from $76.00 to $66.00 and set a “neutral” rating for the company in a report on Thursday, August 28th. Finally, KeyCorp reiterated a “sector weight” rating on shares of Cooper Companies in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $90.31.

Cooper Companies Price Performance

Cooper Companies stock opened at $81.40 on Friday. The stock has a market cap of $16.18 billion, a P/E ratio of 43.30, a price-to-earnings-growth ratio of 1.89 and a beta of 1.05. The company has a fifty day simple moving average of $72.29 and a 200-day simple moving average of $71.74. Cooper Companies has a 12-month low of $61.78 and a 12-month high of $101.53. The company has a current ratio of 2.12, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Thursday, December 4th. The medical device company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.04. Cooper Companies had a net margin of 9.16% and a return on equity of 10.01%. The firm had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the previous year, the firm posted $1.04 earnings per share. The company’s revenue was up 4.6% compared to the same quarter last year. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. Equities analysts expect that Cooper Companies will post 3.98 EPS for the current fiscal year.

Cooper Companies announced that its board has approved a stock repurchase plan on Wednesday, September 17th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical device company to reacquire up to 15.4% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its shares are undervalued.

Insiders Place Their Bets

In other Cooper Companies news, Director Lawrence Erik Kurzius acquired 2,000 shares of the stock in a transaction on Monday, September 29th. The shares were bought at an average cost of $68.39 per share, with a total value of $136,780.00. Following the transaction, the director owned 5,777 shares of the company’s stock, valued at approximately $395,089.03. This trade represents a 52.95% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.98% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Cooper Companies

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Cetera Investment Advisers raised its stake in Cooper Companies by 1.7% during the 1st quarter. Cetera Investment Advisers now owns 24,461 shares of the medical device company’s stock valued at $2,063,000 after acquiring an additional 412 shares during the last quarter. LPL Financial LLC increased its holdings in shares of Cooper Companies by 4.7% in the first quarter. LPL Financial LLC now owns 148,261 shares of the medical device company’s stock valued at $12,506,000 after purchasing an additional 6,657 shares during the period. New Age Alpha Advisors LLC increased its holdings in shares of Cooper Companies by 3,223.5% in the first quarter. New Age Alpha Advisors LLC now owns 13,593 shares of the medical device company’s stock valued at $1,147,000 after purchasing an additional 13,184 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Cooper Companies by 17.0% during the first quarter. Goldman Sachs Group Inc. now owns 4,734,327 shares of the medical device company’s stock worth $399,340,000 after purchasing an additional 686,751 shares during the last quarter. Finally, ASR Vermogensbeheer N.V. acquired a new stake in shares of Cooper Companies during the first quarter worth $304,000. Hedge funds and other institutional investors own 24.39% of the company’s stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.